(Q43585283)

reason for preferred rank

24 November 2017

title

Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine — HGP-30-KLH (English)

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

3 December 2022

Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1823903

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

3 December 2022

author name string

P. H. Naylor

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1823903

3 December 2022

M. B. Sztein

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1823903

3 December 2022

S. Wada

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1823903

3 December 2022

S. Maurer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1823903

3 December 2022

D. Holterman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1823903

3 December 2022

J. E. Kirkley

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1823903

3 December 2022

C. W. Naylor

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1823903

3 December 2022

B. C. Zook

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1823903

3 December 2022

R. A. Hitzelberg

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1823903

3 December 2022

C. J. Gibbs

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1823903

3 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1823903

3 December 2022

publication date

1 January 1991

1 reference

full work available at URL

24 November 2017

https://api.elsevier.com/content/article/PII:019205619190133R?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

https://api.elsevier.com/content/article/PII:019205619190133R?httpAccept=text/plain

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

International Journal of Immunopharmacology

3 December 2022

published in

1 reference

24 November 2017

volume

13 Suppl 1

1 reference

24 November 2017

page(s)

117-127

1 reference

HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals

24 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine

3 December 2022

2

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120

3 December 2022

3

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Immune response and epitope mapping of a candidate hiv-1 p17 vaccine hgp30

3 December 2022

5

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

3 December 2022

AIDS vaccine predictions

6

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

3 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Vaccine protection against simian immunodeficiency virus infection

3 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

3 December 2022

10

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees

3 December 2022

12

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites

3 December 2022

15

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees.

3 December 2022

16

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Expression of human immunodeficiency virus type 1 (HIV-1) gag antigens on the surface of a cell line persistently infected with HIV-1 that highly expresses HIV-1 antigens

3 December 2022

17

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Isotypic restriction of the antibody response to human immunodeficiency virus

3 December 2022

19

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Patterns of antibodies to human immunodeficiency virus proteins in different subclasses of IgG.

3 December 2022

20

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Development and testing of AIDS vaccines

3 December 2022

21

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

In vitro antigen-induced, antigen-specific antibody production in man. Specific and polyclonal components, kinetics, and cellular requirements

3 December 2022

23

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein

3 December 2022

25

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

A formalin-inactivated whole SIV vaccine confers protection in macaques

3 December 2022

26

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides

3 December 2022

30

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping

3 December 2022

31

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1.

3 December 2022

35

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

T cell recognition of HIV synthetic peptides in a natural infection

3 December 2022

36

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study

3 December 2022

38

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Treatment of homosexual men infected with Entamoeba histolytica

3 December 2022

39

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

HIV-specific cytotoxic T lymphocytes in seropositive individuals

3 December 2022

41

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Cytotoxic T lymphocytes against HIV

3 December 2022

42

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis

3 December 2022

43

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

Variable and conserved neutralization antigens of human immunodeficiency virus

3 December 2022

44

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS.

3 December 2022

45

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

The immunology of new generation vaccines

3 December 2022

46

1 reference

https://api.crossref.org/works/10.1016/0192-0561(91)90133-R

3 December 2022

Identifiers

1 reference

24 November 2017

1 reference